AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15517847 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 1005
Study 10962706 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 174
Study 10962706 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching/toning program
Number of subjects: 174
Study 9068154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 79
Study 9068154 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 79
Study 8473426 — intervention group
Group type: EXPERIMENTAL
Intervention: PCO patients
Number of subjects: 76
Study 8473426 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 76
Study 29656132 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision system
Number of subjects: 24
Study 29656132 — intervention group
Group type: EXPERIMENTAL
Intervention: 4K vision system
Number of subjects: 24
Study 29656132 — intervention group
Group type: COMPARATOR
Intervention: 2D vision system
Number of subjects: 24
Study 26923430 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ROM group (cementless modular stem prostheses)
Number of subjects: 65
Study 26923430 — intervention group
Group type: COMPARATOR
Intervention: SLR-PLUS group (cementless coated long-stem prostheses)
Number of subjects: 65
Study 25474278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluoropyrimidine-based chemotherapy
Number of subjects: 229
Study 25474278 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 229
Study 25474278 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd and/or 3rd line chemotherapy with irinotecan and/or cetuximab
Number of subjects: 229
Study 22508711 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg)
Number of subjects: 8
Study 22508711 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion (1 mU/min · kg)
Number of subjects: 8
Study 22508711 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg) + Insulin infusion
Number of subjects: 8
Study 21547174 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 75 μg intravenously as a bolus before induction of anaesthesia
Number of subjects: 60
Study 21547174 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 2.5 mg intravenously as a bolus before induction of anaesthesia
Number of subjects: 60
Study 18717091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage putty-wash impression
Number of subjects: 48
Study 18717091 — intervention group
Group type: COMPARATOR
Intervention: 2-stage putty-wash impression
Number of subjects: 48
Study 18717091 — intervention group
Group type: COMPARATOR
Intervention: Monophase impression
Number of subjects: 48
Study 15745911 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide mouthwash
Number of subjects: 20
Study 15745911 — intervention group
Group type: COMPARATOR
Intervention: Commercially available triamcinolone acetonide paste
Number of subjects: 20
Study 12810240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg tid
Number of subjects: 69
Study 12810240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10026460 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPP patients
Number of subjects: 40
Study 10026460 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPP patients
Number of subjects: 40
Study 10026460 — intervention group
Group type: COMPARATOR
Intervention: Controls (infertile without pain)
Number of subjects: 40
Study 10026460 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPP and ACPP patients
Number of subjects: 40
Study 8739573 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable exercise protocol (GP1)
Number of subjects: 24
Study 8739573 — intervention group
Group type: COMPARATOR
Intervention: Constant exercise protocols (Gps2-4)
Number of subjects: 24
Study 8739573 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of maximum exercise intensity
Number of subjects: 24
Study 8739573 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-HR correlation
Number of subjects: 24
Study 1806619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine, 150-250 mg p.d.
Number of subjects: 26
Study 1806619 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol, 20-40 mg p.d.
Number of subjects: 26
Study 6412376 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution (group A)
Number of subjects: 21
Study 6412376 — intervention group
Group type: COMPARATOR
Intervention: Dextrose‐electrolyte‐calcium solution (group B)
Number of subjects: 21
Study 6412376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 30866088 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 39
Study 30866088 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1500 mg
Number of subjects: 39
Study 28645636 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine (500 mg/day)
Number of subjects: 44
Study 28645636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27339865 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity program delivered by occupational therapists (8 in-home sessions over 3 months)
Number of subjects: 250
Study 27339865 — intervention group
Group type: COMPARATOR
Intervention: Control group intervention delivered by health educators (8 in-home sessions)
Number of subjects: 250
Study 27339865 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity program
Number of subjects: 250
Study 25262372 — intervention group
Group type: EXPERIMENTAL
Intervention: U@Uni intervention
Number of subjects: 0
Study 25262372 — intervention group
Group type: EXPERIMENTAL
Intervention: U@Uni roll-out to another university
Number of subjects: 0
Study 25262372 — intervention group
Group type: EXPERIMENTAL
Intervention: Full implementation of U@Uni
Number of subjects: 0
Study 22723325 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily
Number of subjects: 205
Study 22723325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 22723325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 205
Study 21312292 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 8 mg/day (twice daily)
Number of subjects: 40
Study 21312292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17453688 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Number of subjects: 0
Study 17453688 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 3.75 mg
Number of subjects: 0
Study 15797959 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1000 mg daily), Vitamin D (800 IU daily), and sex steroid replacement therapy (estrogen for females, testosterone for males)
Number of subjects: 99
Study 15797959 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg daily), Vitamin D (800 IU daily), sex steroid replacement therapy (estrogen for females, testosterone for males), and six iv infusions of pamidronate (60 mg each)
Number of subjects: 99
Study 11965557 — intervention group
Group type: EXPERIMENTAL
Intervention: External trunk support
Number of subjects: 10
Study 11965557 — intervention group
Group type: COMPARATOR
Intervention: No external trunk support
Number of subjects: 10
Study 9616311 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia patients
Number of subjects: 20
Study 9616311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy patients
Number of subjects: 20
Study 9616311 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 9616311 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 8745456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy + surgery) in 46 patients
Number of subjects: 100
Study 8745456 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone in 56 patients
Number of subjects: 100
Study 2565582 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (acute: 15 mg; subchronic: 5 mg t.i.d.; Day 7: 5 mg)
Number of subjects: 12
Study 2565582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (acute: 6 mg; subchronic: 2 mg t.i.d.; Day 7: 2 mg)
Number of subjects: 12
Study 2565582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 937075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxin tablets
Number of subjects: 0
Study 937075 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of digoxin
Number of subjects: 0
Study 937075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (tablets and oral solution)
Number of subjects: 0
Study 31984567 — intervention group
Group type: EXPERIMENTAL
Intervention: FM diet (3% purified fibre-mixture)
Number of subjects: 68
Study 31984567 — intervention group
Group type: COMPARATOR
Intervention: CON diet
Number of subjects: 68
Study 31434637 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab + Methotrexate
Number of subjects: 274
Study 27459198 — intervention group
Group type: EXPERIMENTAL
Intervention: NS+oxymetazoline
Number of subjects: 20
Study 27459198 — intervention group
Group type: EXPERIMENTAL
Intervention: oxymetazoline+lidocaine
Number of subjects: 20
Study 27459198 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 20
Study 26853510 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanner B with ASiR and gemstone-based scintillator
Number of subjects: 152
Study 26853510 — intervention group
Group type: COMPARATOR
Intervention: Scanner A (control group)
Number of subjects: 152
Study 24515621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 204
Study 24515621 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched IVIG
Number of subjects: 204
Study 24515621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline + IgM-enriched IVIG
Number of subjects: 204
Study 24515621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 24515621 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 204
Study 22683134 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose regulation
Number of subjects: 1990
Study 22683134 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention
Number of subjects: 1990
Study 22683134 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased β‐cell function
Number of subjects: 1990
Study 22683134 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insulin sensitivity
Number of subjects: 1990
Study 20616624 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy (BDT) added to pharmacotherapy (n = 27)
Number of subjects: 57
Study 20616624 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (n = 30)
Number of subjects: 57
Study 17653509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg
Number of subjects: 64
Study 17653509 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without statin
Number of subjects: 64
Study 16234963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2576
Study 16234963 — intervention group
Group type: COMPARATOR
Intervention: Total hip BMD T score <= -2.5
Number of subjects: 2576
Study 16234963 — intervention group
Group type: COMPARATOR
Intervention: Presence of at least one vertebral fracture
Number of subjects: 2576
Study 16234963 — intervention group
Group type: COMPARATOR
Intervention: Increasing severity of baseline vertebral fractures
Number of subjects: 2576
Study 12097216 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Efficacy Scale (Swedish version) (FES(S))
Number of subjects: 62
Study 12097216 — intervention group
Group type: COMPARATOR
Intervention: Berg Balance Scale (BBS)
Number of subjects: 62
Study 12097216 — intervention group
Group type: COMPARATOR
Intervention: Fugl-Meyer balance subscale (FMB)
Number of subjects: 62
Study 10530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 600 mg, 1200 mg, or 2400 mg daily
Number of subjects: 649
Study 10530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 300 mg/day or 3600 mg/day
Number of subjects: 649
Study 10530677 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (GBP) 300 mg/day, 900 mg/day, or 1800 mg/day
Number of subjects: 649
Study 7502570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg piroximone
Number of subjects: 40
Study 7502570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg piroximone
Number of subjects: 40
Study 7502570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg piroximone
Number of subjects: 40
Study 7502570 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg piroximone
Number of subjects: 40
Study 7502570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 2274638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 80 to 120 mg per day
Number of subjects: 30
Study 6988222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 7
Study 6988222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31058913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (calcium-free phosphate binder)
Number of subjects: 4721
Study 31058913 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (calcium-based phosphate binder)
Number of subjects: 4721
Study 28820635 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell infusion after FOLFOX4 chemotherapy
Number of subjects: 46
Study 28820635 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 chemotherapy
Number of subjects: 46
Study 25554820 — intervention group
Group type: EXPERIMENTAL
Intervention: Late cranial ultrasound (CUS)
Number of subjects: 480
Study 25554820 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-term brain MRI
Number of subjects: 480
Study 25554820 — intervention group
Group type: COMPARATOR
Intervention: Early cranial ultrasound (CUS)
Number of subjects: 480
Study 23673400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudouridine
Number of subjects: 30
Study 23673400 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite-based prognostic models
Number of subjects: 30
Study 23673400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic acid metabolites
Number of subjects: 30
Study 23673400 — intervention group
Group type: COMPARATOR
Intervention: Pseudouridine in liver and kidney homogenates from CLP mice
Number of subjects: 30
Study 22141609 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arc VMAT
Number of subjects: 8
Study 22141609 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-arc VMAT
Number of subjects: 8
Study 22141609 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 8
Study 22141609 — intervention group
Group type: COMPARATOR
Intervention: Conformal plans
Number of subjects: 8
Study 22141609 — intervention group
Group type: EXPERIMENTAL
Intervention: Two VMAT techniques
Number of subjects: 8
Study 22141609 — intervention group
Group type: EXPERIMENTAL
Intervention: Static gantry IMRT
Number of subjects: 8
Study 19136105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive colonoscopic surveillance (ICS group, n = 165)
Number of subjects: 326
Study 19136105 — intervention group
Group type: COMPARATOR
Intervention: Routine colonoscopic surveillance (RCS group, n = 161)
Number of subjects: 326
Study 16707911 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) substitution therapy for 6 months
Number of subjects: 13
Study 16707911 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy for 6 months
Number of subjects: 13
Study 14762406 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient-controlled alert device
Number of subjects: 150
Study 14762406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-holding
Number of subjects: 150
Study 14762406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both communication methods (hand-holding and alert device)
Number of subjects: 150
Study 14762406 — intervention group
Group type: COMPARATOR
Intervention: All groups (electronic alert device, hand-holding, both)
Number of subjects: 150
Study 10486672 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (dihydropyridines, diltiazem, verapamil, bepridil)
Number of subjects: 112792
Study 10486672 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (subgroup analysis in patients over 65 years old)
Number of subjects: 112792
Study 10486672 — intervention group
Group type: COMPARATOR
Intervention: Salicylates and non-steroidal anti-inflammatory drugs
Number of subjects: 112792
Study 8610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin, 500 mg three times daily for 20 days
Number of subjects: 246
Study 8610947 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin, 500 mg once daily for 7 days
Number of subjects: 246
Study 8610947 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 246
Study 8610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 246
Study 8610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial response at day 20
Number of subjects: 246
Study 8610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple erythema migrans lesions
Number of subjects: 246
Study 8610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse
Number of subjects: 246
Study 2023353 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B sulfate, neomycin sulfate, and vancomycin hydrochloride (PNV) administered six times daily in the oropharynx.
Number of subjects: 52
Study 2023353 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered six times daily in the oropharynx.
Number of subjects: 52
Study 6758744 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional propranolol (160 or 320 mg once daily)
Number of subjects: 15
Study 6758744 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting propranolol (160 or 320 mg once daily)
Number of subjects: 15
Study 6758744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6758744 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional and long acting propranolol
Number of subjects: 15
Study 30265168 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 300
Study 30265168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 300
Study 30265168 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 300
Study 30265168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 300
Study 27696762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 197
Study 27696762 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid exposure
Number of subjects: 197
Study 27696762 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity improvement
Number of subjects: 197
Study 24837493 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA Dx injection therapy
Number of subjects: 136
Study 22515885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 70
Study 22515885 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 70
Study 20441408 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-α hydroxyprogesterone caproate (17OHPC)
Number of subjects: 221
Study 18047459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic pneumatic soft‐tissue compression during the 6‐week immobilisation period
Number of subjects: 21
Study 18047459 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 21
Study 18047459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic pneumatic soft‐tissue compression
Number of subjects: 21
Study 16044026 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2.0 microg/kg SC
Number of subjects: 33
Study 16044026 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 3.0 microg/kg SC
Number of subjects: 33
Study 16044026 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 5.0 microg/kg SC
Number of subjects: 33
Study 16044026 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa 0.75 microg/kg SC
Number of subjects: 33
Study 12237203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency, high intensity, extrasegmental stimulation
Number of subjects: 240
Study 12237203 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency, 'strong but comfortable' intensity, segmental stimulation
Number of subjects: 240
Study 12237203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of segmental and extrasegmental stimulation
Number of subjects: 240
Study 12237203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 12237203 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 240
Study 10073719 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1838
Study 10073719 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 1838
Study 10073719 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 1838
Study 8821297 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarosan (benzyl benzoate) and vapour permeable waterproof fabric encasement
Number of subjects: 56
Study 8821297 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment and cotton covers encasement
Number of subjects: 56
Study 8821297 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarosan applied to carpets or inside mattress covers
Number of subjects: 56
Study 8821297 — intervention group
Group type: EXPERIMENTAL
Intervention: Encasing covers
Number of subjects: 56
Study 2074254 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 1 g cefodizime
Number of subjects: 12
Study 2074254 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intravenous infusions of 1 g cefodizime twice daily for 4.5 days
Number of subjects: 12
Study 7044069 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg or 150 mg/day)
Number of subjects: 35